instruction
stringlengths 4
15.8k
| input
stringclasses 1
value | output
stringlengths 1
5.09k
| text
stringlengths 152
16.1k
|
|---|---|---|---|
Stroke prevention?
|
f or resear ch
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Stroke prevention?. ### Response: f or resear ch.
|
|
Rat and rh ythm contr ol?
|
Management f or people pr esenting acut ely wit h atrial fibrillation ........................................... 20 1.9 Initial management of str oke and atrial fibrillation ..................................................................... 22 1.10 Pr eventing and managing post operativ e atrial fibrillation ....................................................... 23 1.11 St opping anticoagulation ............................................................................................................. 25 Terms used in t his guideline ............................................................................................................... 25 Recommendations f or resear ch
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Rat and rh ythm contr ol?. ### Response: Management f or people pr esenting acut ely wit h atrial fibrillation ........................................... 20 1.9 Initial management of str oke and atrial fibrillation ..................................................................... 22 1.10 Pr eventing and managing post operativ e atrial fibrillation ....................................................... 23 1.11 St opping anticoagulation ............................................................................................................. 25 Terms used in t his guideline ............................................................................................................... 25 Recommendations f or resear ch.
|
|
How many terms are used in t his guideline?
|
25
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many terms are used in t his guideline?. ### Response: 25.
|
|
How many Recommendations f or resear?
|
27
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many Recommendations f or resear?. ### Response: 27.
|
|
What are the key recommendations for f or resear ch?
|
27
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are the key recommendations for f or resear ch?. ### Response: 27.
|
|
What is the risk of stroke?
|
31 Bleeding risk
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the risk of stroke?. ### Response: 31 Bleeding risk.
|
|
What is a direct renin inhibitor versusplacebo?
|
Adults with CKD
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is a direct renin inhibitor versusplacebo?. ### Response: Adults with CKD.
|
|
What is an aliskiren versus ACEi or ARBTable?
|
ACEi DARB
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is an aliskiren versus ACEi or ARBTable?. ### Response: ACEi DARB.
|
|
Adults with diabetes and CKD, high-dose potassium binder versus what?
|
low-dosepotassium binder
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Adults with diabetes and CKD, high-dose potassium binder versus what?. ### Response: low-dosepotassium binder.
|
|
What type of diet are kidney transplant recipients compared to?
|
low-salt
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What type of diet are kidney transplant recipients compared to?. ### Response: low-salt.
|
|
What is the difference between a Mediterranean diet and a low-fat diet?
|
Kidney transplant recipients
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the difference between a Mediterranean diet and a low-fat diet?. ### Response: Kidney transplant recipients.
|
|
Kidney transplant recipients, ARB versus calcium channel blockersTable S94.
|
ACEi
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Kidney transplant recipients, ARB versus calcium channel blockersTable S94.. ### Response: ACEi.
|
|
What is ACEi versus ARBTable Table S95?
|
ACEi Dcalcium channel blockers
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is ACEi versus ARBTable Table S95?. ### Response: ACEi Dcalcium channel blockers.
|
|
What are kidney transplant recipients comparing to?
|
low-salt diet versus usual or normal-salt dietTable S90. Kidney transplant recipients, Mediterranean diet versus low-fat diet
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are kidney transplant recipients comparing to?. ### Response: low-salt diet versus usual or normal-salt dietTable S90. Kidney transplant recipients, Mediterranean diet versus low-fat diet.
|
|
Channel blockers versus calcium channel blockers aloneTable S97.
|
ACEi Dcalcium
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Channel blockers versus calcium channel blockers aloneTable S97.. ### Response: ACEi Dcalcium.
|
|
Kidney transplant recipients, ACEi DARB versus ARB alone Table S99.
|
placebo or no treatmentTable S100
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Kidney transplant recipients, ACEi DARB versus ARB alone Table S99.. ### Response: placebo or no treatmentTable S100.
|
|
What are kidney transplant recipients referred to as?
|
ACE
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are kidney transplant recipients referred to as?. ### Response: ACE.
|
|
What is a kidney transplant recipient called?
|
ACEi
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is a kidney transplant recipient called?. ### Response: ACEi.
|
|
What is ACEi versus?
|
calcium channel blockers
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is ACEi versus?. ### Response: calcium channel blockers.
|
|
What is ARB versus beta-blocker?
|
calcium channel blockers
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is ARB versus beta-blocker?. ### Response: calcium channel blockers.
|
|
Which kidney transplant recipients have calcium channel blockers versus thiazide?
|
Kidney transplant recipients, calcium channel blockers versus thiazideTable S106
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Which kidney transplant recipients have calcium channel blockers versus thiazide?. ### Response: Kidney transplant recipients, calcium channel blockers versus thiazideTable S106.
|
|
What is the difference between channel blockers and thiazide?
|
calcium
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the difference between channel blockers and thiazide?. ### Response: calcium.
|
|
What are the differences between kidney transplant recipients and placebo?
|
no treatment, or standard of care
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are the differences between kidney transplant recipients and placebo?. ### Response: no treatment, or standard of care.
|
|
Where is Kidney International located?
|
2021) 99, S1–S87
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Where is Kidney International located?. ### Response: 2021) 99, S1–S87.
|
|
What does not apply to non-life-threatening bleeding?
|
recommendation
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What does not apply to non-life-threatening bleeding?. ### Response: recommendation.
|
|
What did we find no systematic review of?
|
this question
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What did we find no systematic review of?. ### Response: this question.
|
|
How many studies did we identify that addressed this question?
|
3
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many studies did we identify that addressed this question?. ### Response: 3.
|
|
How many patients received idarucizumab?
|
none
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many patients received idarucizumab?. ### Response: none.
|
|
What did we combine the number of events and the total number of patients from the 3studies to calculate?
|
a relative effect
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What did we combine the number of events and the total number of patients from the 3studies to calculate?. ### Response: a relative effect.
|
|
How many studies included patients receiving dabigatran presenting with life-threatening bleeding?
|
1study195
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many studies included patients receiving dabigatran presenting with life-threatening bleeding?. ### Response: 1study195.
|
|
What is urgently needed for invasive procedures?
|
dabigatran reversal
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is urgently needed for invasive procedures?. ### Response: dabigatran reversal.
|
|
Allstudies reported the outcomes of life-threatening bleeding associ-ated with what?
|
dabigatran therapy
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Allstudies reported the outcomes of life-threatening bleeding associ-ated with what?. ### Response: dabigatran therapy.
|
|
What is shown online at https://dbep.gradepro.org/profile/b1deb68f-2ed2-4734-bb86-0a66117969cd?
|
EtD framework
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is shown online at https://dbep.gradepro.org/profile/b1deb68f-2ed2-4734-bb86-0a66117969cd?. ### Response: EtD framework.
|
|
What may or may not reduce themortality risk?
|
Idarucizumab administration
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What may or may not reduce themortality risk?. ### Response: Idarucizumab administration.
|
|
What is the RR of Idarucizumab?
|
0.47
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the RR of Idarucizumab?. ### Response: 0.47.
|
|
What is the risk of life-threatening bleeding during dabigatran therapy?
|
death
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the risk of life-threatening bleeding during dabigatran therapy?. ### Response: death.
|
|
What are the CIs very wide and include large risk reductions and increases?
|
Harms and burden
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are the CIs very wide and include large risk reductions and increases?. ### Response: Harms and burden.
|
|
How many VTE events were reported following idarucizumab administration in 1 study?
|
5
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many VTE events were reported following idarucizumab administration in 1 study?. ### Response: 5.
|
|
What was not possible because there were no VTEs in the comparison group?
|
Estimating the relative and absolute risk estimates
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was not possible because there were no VTEs in the comparison group?. ### Response: Estimating the relative and absolute risk estimates.
|
|
The certainty in theseestimated effects is what?
|
very low
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The certainty in theseestimated effects is what?. ### Response: very low.
|
|
What is the certainty in theseestimated effects?
|
very low
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the certainty in theseestimated effects?. ### Response: very low.
|
|
The acquisitioncost of idarucizumab is considerable, although no formal economicanalyses are available?
|
the cost likely outweighs the potential benefit
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The acquisitioncost of idarucizumab is considerable, although no formal economicanalyses are available?. ### Response: the cost likely outweighs the potential benefit.
|
|
There is very low certainty evidence for a net health benefit from using what drug?
|
Idarucizumab
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: There is very low certainty evidence for a net health benefit from using what drug?. ### Response: Idarucizumab.
|
|
What is the benefit of usingidarucizumab to manage life-threatening bleeding for patients re-ceiving dabigatran therapy for VTE?
|
net health benefit
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the benefit of usingidarucizumab to manage life-threatening bleeding for patients re-ceiving dabigatran therapy for VTE?. ### Response: net health benefit.
|
|
Some panel members were concerned about thepossibility of VTE following what?
|
idarucizumab administration
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Some panel members were concerned about thepossibility of VTE following what?. ### Response: idarucizumab administration.
|
|
The cost likely outweighs the potential benefit from using what drug?
|
Idarucizumab
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: The cost likely outweighs the potential benefit from using what drug?. ### Response: Idarucizumab.
|
|
What does the cost of idarucizumab likely outweigh the potential benefit of?
|
non –life-threatening bleeding
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What does the cost of idarucizumab likely outweigh the potential benefit of?. ### Response: non –life-threatening bleeding.
|
|
What variables define the need for intervention with overholding dabigatran alone?
|
death, worsening and/orrecurrence of bleeding, and thromboembolic complications
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What variables define the need for intervention with overholding dabigatran alone?. ### Response: death, worsening and/orrecurrence of bleeding, and thromboembolic complications.
|
|
What should not be used in patients with HF or LV systolic dysfunc-tion?
|
Diltiazem or verapamil
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What should not be used in patients with HF or LV systolic dysfunc-tion?. ### Response: Diltiazem or verapamil.
|
|
What should be avoided because of its short-acting effect?
|
nifedipine
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What should be avoided because of its short-acting effect?. ### Response: nifedipine.
|
|
What should be avoided because it causes reflex sympathetic activation and worsening myocardial ischemia?
|
short-acting nifedipine
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What should be avoided because it causes reflex sympathetic activation and worsening myocardial ischemia?. ### Response: short-acting nifedipine.
|
|
What is useful in the management of hypertension in patients with stable angina?
|
CCBs
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is useful in the management of hypertension in patients with stable angina?. ### Response: CCBs.
|
|
There is no consensus about what role CCBs play in preventing cardiovascular events?
|
their role in preventing cardiovascular events in patients with established CAD
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: There is no consensus about what role CCBs play in preventing cardiovascular events?. ### Response: their role in preventing cardiovascular events in patients with established CAD.
|
|
How many hypertensive patients with chronic CAD were randomized to the non-dihydropyridine CCB verapamil or the -blocker atenolol?
|
>22 000
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many hypertensive patients with chronic CAD were randomized to the non-dihydropyridine CCB verapamil or the -blocker atenolol?. ### Response: >22 000.
|
|
What was the ACE inhibitor trandolapril added to by 24 months?
|
63% of verapamil patients and 52% of atenolol patients
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was the ACE inhibitor trandolapril added to by 24 months?. ### Response: 63% of verapamil patients and 52% of atenolol patients.
|
|
What was added to 44% of verapamil patients?
|
hydrochlorothiazide
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was added to 44% of verapamil patients?. ### Response: hydrochlorothiazide.
|
|
What percentage of atenolol patients were treated with hydrochlorothiazide?
|
60%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What percentage of atenolol patients were treated with hydrochlorothiazide?. ### Response: 60%.
|
|
How long did the follow-up of the study last?
|
4.2 years
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How long did the follow-up of the study last?. ### Response: 4.2 years.
|
|
How long was the mean follow-up of ALLHAT patients?
|
2.7 years
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How long was the mean follow-up of ALLHAT patients?. ### Response: 2.7 years.
|
|
What percentage of patients had a history or signs of atherosclerotic vascular disease?
|
More than 50%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What percentage of patients had a history or signs of atherosclerotic vascular disease?. ### Response: More than 50%.
|
|
There was no significant difference in the inci-dence of coronary end points among patients allocated what?
|
a thiazide-type diuretic, a long-acting dihydropyridine CCB, or an ACE inhibitor
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: There was no significant difference in the inci-dence of coronary end points among patients allocated what?. ### Response: a thiazide-type diuretic, a long-acting dihydropyridine CCB, or an ACE inhibitor.
|
|
What is a diuretic?
|
thiazide-type
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is a diuretic?. ### Response: thiazide-type.
|
|
What is an ACE inhibitor?
|
trandolapril
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is an ACE inhibitor?. ### Response: trandolapril.
|
|
Who compared amlodipine or enalapril with placebo?
|
CAMELOT
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Who compared amlodipine or enalapril with placebo?. ### Response: CAMELOT.
|
|
How much of the normotensive patients with CAD had a history of hypertension?
|
≈60%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How much of the normotensive patients with CAD had a history of hypertension?. ### Response: ≈60%.
|
|
What group had less adverse cardiovascular events than the enalapril group?
|
amlodipine
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What group had less adverse cardiovascular events than the enalapril group?. ### Response: amlodipine.
|
|
What was the result of an intravascu-lar ultrasound substudy of CAMELOT?
|
progression of atherosclerosis
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was the result of an intravascu-lar ultrasound substudy of CAMELOT?. ### Response: progression of atherosclerosis.
|
|
In what group did a trend toward progression occur in atherosclerosis?
|
enalapril group
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: In what group did a trend toward progression occur in atherosclerosis?. ### Response: enalapril group.
|
|
What group had no progression in the amlodipine group?
|
placebo
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What group had no progression in the amlodipine group?. ### Response: placebo.
|
|
What may have pleiotropic effects beyond BP lowering that favor atherosclerotic plaque stabilization?
|
Amlodipine
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What may have pleiotropic effects beyond BP lowering that favor atherosclerotic plaque stabilization?. ### Response: Amlodipine.
|
|
How many hypertensive patients at high risk of cardiac events were randomized to valsartan?
|
15 245
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many hypertensive patients at high risk of cardiac events were randomized to valsartan?. ### Response: 15 245.
|
|
Forty-six percent of patients in both groups had what?
|
CAD
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: Forty-six percent of patients in both groups had what?. ### Response: CAD.
|
|
What percentage of patients in both groups had CAD?
|
Forty-six percent
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What percentage of patients in both groups had CAD?. ### Response: Forty-six percent.
|
|
How long was the mean follow-up?
|
4.2 years
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How long was the mean follow-up?. ### Response: 4.2 years.
|
|
What was the primary composite end point of cardiac mor-bidity and mortality?
|
thiazide-type diuretic, a long-acting dihydropyridine CCB, or an ACE inhibitor
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was the primary composite end point of cardiac mor-bidity and mortality?. ### Response: thiazide-type diuretic, a long-acting dihydropyridine CCB, or an ACE inhibitor.
|
|
In which group was the risk of MI lower?
|
amlodip-ine
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: In which group was the risk of MI lower?. ### Response: amlodip-ine.
|
|
What was lower in the valsartan group?
|
the risk of new-onset diabetes mellitus
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was lower in the valsartan group?. ### Response: the risk of new-onset diabetes mellitus.
|
|
What drug was signifi-cative for diabetes mellitus?
|
valsartan
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What drug was signifi-cative for diabetes mellitus?. ### Response: valsartan.
|
|
What is performed after PCI?
|
while the patient is receiving DAPT).
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is performed after PCI?. ### Response: while the patient is receiving DAPT)..
|
|
What may be associated with lower graft patency rates compared with CABG performedthrough a midline sternotomy?
|
minimally invasive CABG
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What may be associated with lower graft patency rates compared with CABG performedthrough a midline sternotomy?. ### Response: minimally invasive CABG.
|
|
How many RCTs have been published to date involving hybrid coronary revascularization?
|
no
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How many RCTs have been published to date involving hybrid coronary revascularization?. ### Response: no.
|
|
How long have retrospective series of hybrid re-vascularization reported low mor-tality rates?
|
10 years
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How long have retrospective series of hybrid re-vascularization reported low mor-tality rates?. ### Response: 10 years.
|
|
What are event-free survival rates at 6-12 months?
|
83% to92%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are event-free survival rates at 6-12 months?. ### Response: 83% to92%.
|
|
What is the survival rate of a PCI procedure at 6 to 12 months of follow-up?
|
83% to92%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the survival rate of a PCI procedure at 6 to 12 months of follow-up?. ### Response: 83% to92%.
|
|
How long does it take for a hybrid coronary revascularization to have a similar outcome?
|
30 days and6 months
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How long does it take for a hybrid coronary revascularization to have a similar outcome?. ### Response: 30 days and6 months.
|
|
What are the three components that define a successful PCI?
|
angiographic findings, proceduralevents, and clinical outcomes
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are the three components that define a successful PCI?. ### Response: angiographic findings, proceduralevents, and clinical outcomes.
|
|
What are the three components of a PCI procedure?
|
angiographic findings, proceduralevents, and clinical outcomes
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are the three components of a PCI procedure?. ### Response: angiographic findings, proceduralevents, and clinical outcomes.
|
|
What does a successful PCI produce to improve coronary artery bloodflow?
|
sufficient enlargement of thelumen
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What does a successful PCI produce to improve coronary artery bloodflow?. ### Response: sufficient enlargement of thelumen.
|
|
How is a balloon angioplasty defined?
|
thereduction of a minimum stenosis diameter to /H1102150% with afinal TIMI flow grade 3
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How is a balloon angioplasty defined?. ### Response: thereduction of a minimum stenosis diameter to /H1102150% with afinal TIMI flow grade 3.
|
|
What is the minimum stenosis diameter for coronary stents?
|
/H1102110%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is the minimum stenosis diameter for coronary stents?. ### Response: /H1102110%.
|
|
What has previously been the clinical benchmark of an optimal angio-graphic result?
|
a minimum stenosisdiameter of /H1102120%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What has previously been the clinical benchmark of an optimal angio-graphic result?. ### Response: a minimum stenosisdiameter of /H1102120%.
|
|
What was the clinical benchmark of an optimal angio-graphic result?
|
Procedural Success
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What was the clinical benchmark of an optimal angio-graphic result?. ### Response: Procedural Success.
|
|
What did the writing committee conclude about a minimum diameter stenosis?
|
should be thenew benchmark for lesions treated with coronary stenting
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What did the writing committee conclude about a minimum diameter stenosis?. ### Response: should be thenew benchmark for lesions treated with coronary stenting.
|
|
What should be the new benchmark for lesions treated with coronary stenting?
|
a minimum diameter stenosis of /H1102110%
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What should be the new benchmark for lesions treated with coronary stenting?. ### Response: a minimum diameter stenosis of /H1102110%.
|
|
What should there be final TIMI flowgrade 3 without?
|
occlusion of a significant side branch,flow-limiting dissection, distal embolization, or angiographicthrombus
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What should there be final TIMI flowgrade 3 without?. ### Response: occlusion of a significant side branch,flow-limiting dissection, distal embolization, or angiographicthrombus.
|
|
What are some of the problems with determining angiographic success?
|
disparities between the visual assessment andcomputer-aided quantitative stenosis measurement and self-reporting of success in clinical reports or databases
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are some of the problems with determining angiographic success?. ### Response: disparities between the visual assessment andcomputer-aided quantitative stenosis measurement and self-reporting of success in clinical reports or databases.
|
|
What is a problem with the visual assessment and computer-aided quantitative stenosis measurement?
|
disparities
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What is a problem with the visual assessment and computer-aided quantitative stenosis measurement?. ### Response: disparities.
|
|
How should a successful PCI achieve success with-out associated in-hospital complications?
|
Procedural Success
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: How should a successful PCI achieve success with-out associated in-hospital complications?. ### Response: Procedural Success.
|
|
What are major clinical complications?
|
death, MI, stroke, emergency CABG
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are major clinical complications?. ### Response: death, MI, stroke, emergency CABG.
|
|
What are discussed in Sections 3.3 and 5.10.3.1.3?
|
Issues regarding thediagnosis and prognostic implications of procedure-relatedMI
|
Below is an instruction that describes a task. Write a response that appropriately completes the request. ### Instruction: What are discussed in Sections 3.3 and 5.10.3.1.3?. ### Response: Issues regarding thediagnosis and prognostic implications of procedure-relatedMI.
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.